Diffuse pediatric-type high grade glioma, RTK1 subtype, subclass C with SYN2 :: PPARG fusion in an older adult.

CNS OncolMar 25, 2026 (epub)
Case ReportOncology (Medical)NeurologyOpen access

Mikaela N Brentlinger, Jemini Patel, Ahmed Khan et al.

✦ AI-curated · Sources linked

Case in brief

A 66-year-old woman presented with a left frontal lobe mass and underwent surgical resection. Histology showed a high-grade glioma with pleomorphism, brisk mitotic activity, vascular proliferation and necrosis, alongside oligodendroglial-like features, nuclear clusters and small rosette-like structures. Molecular testing identified several genomic alterations, including a SYN2::PPARG fusion; DNA methylation profiling classified the tumor as diffuse pediatric-type high-grade glioma, RTK1 subtype, subclass C. After surgery, she developed herpes simplex virus 2 meningoencephalitis and died.

What made this case unusual

The tumor was classified as a pediatric-type high-grade glioma in a 66-year-old adult, and testing identified a SYN2::PPARG fusion not previously reported in glioma.

Diagnostic / clinical pearl

In an older adult with an atypical high-grade glioma, integrating histology with molecular testing and DNA methylation profiling can clarify tumor classification.

Source

PubMed · PMID 41877551Free full text on PubMed Central

Published in CNS Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.